Stereotactic body radiation therapy in hepatocellular carcinoma and cirrhosis: Evaluation of radiological and pathological response

Facciuto, Marcelo; Singh, Manoj Kumar; Rochon, Caroline; Sharma, Jyoti; Gimenez, Cecilia; Katta, Umadevi S.; Moorthy, Chitti R.; Bentley–Hibbert, Stuart; Rodríguez-Dávalos, Manuel I.; Wolf, David C.

doi:10.1002/jso.22104

Cited by 74 publications

(50 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…SBRT may help reduce this: following SBRT used as a bridging therapy, 63-100% of patients are reported to proceed to transplant, with low rates of toxicity, and with complete and partial pathological responses reported in 14-29% and 23-64% of lesions respectively [39][40][41][42][43] . Mohamed et al recently compared SBRT, TACE, RFA and yttrium-90 microspheres as bridge to transplant therapies in a retrospective series of 60 patients 43 .…”

Section: Sbrt As a Bridge To Transplantmentioning

confidence: 99%

Advances in Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma

Murray

Dawson

2017

Seminars in Radiation Oncology

View full text Add to dashboard Cite

SBRT is an emerging effective treatment for hepatocellular carcinoma (HCC) associated with acceptable rates of toxicity in appropriately selected patients. Despite often being reserved for patients unsuitable for other local treatments, prospective and retrospective studies have demonstrated excellent long-term control. SBRT may be used as a stand-alone treatment, or as an adjunct to other HCC therapies. Based on available data, SBRT appears to complement existing local liver therapies.Randomised and non-randomized comparative studies are required to better determine the optimal role of SBRT in HCC treatment.

show abstract

Section: Sbrt As a Bridge To Transplantmentioning

confidence: 99%

Advances in Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma

Murray

Dawson

2017

Seminars in Radiation Oncology

View full text Add to dashboard Cite

show abstract

“…[18][19][20][21][22] Other publications apply recommended EASL or mRECIST criteria. [23][24][25][26][27] A single article compared the RECIST and EASL criteria in this indication. Price et al reported in 2012 on a series of 26 patients treated for 29 CHC by SBRT by comparing the morphological evolution according to the RECIST and EASL criteria 16 ( Table 1).…”

Section: Evaluation Of Response After Sbrt For Primary Hepatic Tumorsmentioning

confidence: 99%

Evaluation of response after SBRT for liver tumors

Tétreau

Llacer

Riou

et al. 2017

Reports of Practical Oncology & Radiotherapy

View full text Add to dashboard Cite

Use of RECIST criteria is also inadequate in the evaluation of response after SBRT for hepatic metastases. Response of liver metastases to SBRT is better assessed with a combination of size and enhancement pattern. The occurrence of a lobulated enhancement during follow up is efficient to predict local progression in a specific, reproducible, and sensitive way. Patients with FDG-avid hepatic metastases are also better evaluated with PET-CT and functional criteria than routine imaging and metric evaluation alone.

show abstract

“…Facciuto et al [82] provided excellent clinicopathologic correlation among 39 lesions in 27 patients receiving SBRT as bridge therapy prior to OLT. Patients received 24-36 Gy divided in two to four fractions using Novalis-based radiosurgery with image guidance and fiducial marker placement.…”

Section: Recent Experience With Sbrt For Plcmentioning

confidence: 99%

External radiation treatment of malignant liver disease: a critical review

et al. 2012

View full text Add to dashboard Cite

Introduction Owing to the liver's integral role in biosynthesis and homeostasis, management of primary and secondary malignancies arising in this organ is of paramount oncologic significance. Over the past several decades, substantial progress has been achieved in the imaging and treatment of early and advanced hepatic malignancies. Radiation therapy (RT) has recently emerged as one of many local therapeutic options for both primary and metastatic liver cancer. Recent phase I and II studies describe promising efficacy and side effect profile; however, phase III studies are needed to establish RT among standard of care therapeutic modalities. Purpose In this review, we will describe (a) the scope, epidemiology, and standard treatment options for liver cancer; (b) relevant diagnostic imaging techniques; and (c) provide an in-depth review of RT treatment techniques, dose-volume limits of normal tissues, and results of both conventional and hypofractionated RT liver trials pertaining to primary and secondary liver cancers with emphasis on three-dimensional conformal radiation therapy (3DCRT) and stereotactic body radiotherapy (SBRT) studies.

show abstract

Stereotactic body radiation therapy in hepatocellular carcinoma and cirrhosis: Evaluation of radiological and pathological response

Cited by 74 publications

References 58 publications

Advances in Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma

Advances in Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma

Evaluation of response after SBRT for liver tumors

External radiation treatment of malignant liver disease: a critical review

Contact Info

Product

Resources

About